Breaking News Headlines Today

News from Eyewire+

Stay current with all the latest and breaking news from Eyewire+. Compare headlines and media bias behind news outlets on stories breaking today.

In total, 114 have been published by Eyewire+ which Ground News has aggregated in the past 3 months.

Eyewire+’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Eyewire+’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Eyewire+

Where is Eyewire+ located?Eyewire+'s Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Eyewire+ News

Why Is STAAR Surgical Stock Skyrocketing Tuesday? - Staar Surgical (NASDAQ:STAA), Alcon (NYSE:ALC)

86% Center coverage: 7 sources

Alcon will acquire STAAR Surgical for $1.5 billion to expand surgical vision correction options for high myopia, including EVO ICL lenses.See the Story

United States · United States

FDA Approves Once-Daily Vizz for Presbyopia

100% Center coverage: 1 sources

The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz Therapeutics.Once-daily Vizz (aceclidine ophthalmic solution 1.44%) contracts the iris sphincter muscle, creating a pinhole effect to extend depth of focus and improve near vision without a myopic shift, according to the release.See the Story

New York State · New York

Ocular Therapeutix Secures FDA Special Protocol Assessment for NPDR Trial of Axpaxli

Ocular Therapeutix has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the registrational trial design of Axpaxli (OTX-TKI) for the treatment of nonproliferative diabetic retinopathy (NPDR). Axpaxli (OTX-TKI) is an investigational, bioresorbable intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, under development for wet AM…Read Article

PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHT

PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). PA5108 is a new chemical entity (NCE) and prodrug of latanoprost acid engineered to deliver consistent IOP-lowering therapy over a 6-month period following a sing…United States · United States Read Article

LKC Technologies: RETeval DR Score Superior in Predicting Diabetic Retinopathy Outcomes

LKC Technologies, a provider of electroretinography (ERG)-based functional diagnostics, announced the publication of a study that found that ERG/pupillometry outperforms structural imaging in identifying patients at highest risk of progressing to vision-threatening complications over 1 year. The post-hoc analysis, which evaluated 56 parameters across four modalities: ERG/pupillometry, UWF-FA, OCTA, and fundus photography, was published in Ophtha…Read Article

4DMT Provides New 60-Week Results for Gene Therapy Candidate for DME

4D Molecular Therapeutics (4DMT) announced interim results from its SPECTRA phase 2a clinical trial evaluating 4D-150 for diabetic macular edema (DME). The data were presented at the 43rd Annual American Society of Retina Specialists (ASRS) scientific meeting by David Almeida, MD, PhD.[1] Key Takeaways 1. Durable Visual and Anatomic Response at Phase 3 Dose Patients receiving the Phase 3 dose (3E10 vg/eye) of 4D-150 demonstrated: +9.7 letter…FDA · Maryland Read Article

New Study Links Physical Activity to Slower Glaucoma Progression

A new study has revealed that higher levels of physical activity may significantly slow the progression of visual field loss in individuals with glaucoma. The findings suggest that lifestyle modifications could become an important complement to traditional glaucoma treatments. In a study published in the Journal of Glaucoma, researchers sought to examine whether physical activity levels were associated with the rate of visual field deterioration…Read Article

Mark Maire Appointed CEO of Rebion

Rebion, a provider of neuro-visual diagnostics and digital retinal imaging technologies, announced the appointment of Mark Maire as Chief Executive Officer. Mr. Maire brings more than two decades of commercial leadership and strategic growth experience, including the sale of TrueVision Systems to Alcon, and the expansion of surgical imaging solutions at Cassini Technologies. As CEO, Mr. Maire will lead Rebion's next phase of growth, with an imme…Maryland · Maryland Read Article

News from Eyewire+

News from Eyewire+

Information about Eyewire+

Media Bias Ratings

Factuality

Ownership

Top Eyewire+ News

Why Is STAAR Surgical Stock Skyrocketing Tuesday? - Staar Surgical (NASDAQ:STAA), Alcon (NYSE:ALC)

FDA Approves Once-Daily Vizz for Presbyopia

Ocular Therapeutix Secures FDA Special Protocol Assessment for NPDR Trial of Axpaxli

First FDA-Approved Treatment for MacTel Performed

Genentech reports five-year data from trial of Susvimo for wet AMD

Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Report

PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHT

LKC Technologies: RETeval DR Score Superior in Predicting Diabetic Retinopathy Outcomes

4DMT Provides New 60-Week Results for Gene Therapy Candidate for DME

New Study Links Physical Activity to Slower Glaucoma Progression

Mark Maire Appointed CEO of Rebion

Similar News Topics

Topics Most Covered by Eyewire+

Sources Covering Similar Topics

Breaking News Topics Related to Eyewire+

Information about Eyewire+

Media Bias Ratings

Factuality

Ownership

First FDA-Approved Treatment for MacTel Performed

Genentech reports five-year data from trial of Susvimo for wet AMD

Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Report

PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHT

LKC Technologies: RETeval DR Score Superior in Predicting Diabetic Retinopathy Outcomes

4DMT Provides New 60-Week Results for Gene Therapy Candidate for DME

New Study Links Physical Activity to Slower Glaucoma Progression

Mark Maire Appointed CEO of Rebion